Mouse
immunization
and serum
screening |
Fusion, primary
and secondary
hybridoma
screening |
Cloning and
characterization
of hybridomas |
Antibody Scaleup
Production/
Purification |
Antisera from mice
immunized with your
immunogen are used to
develop a screening
assay for the selection
of specific antibody
secreting hybridoma
cell lines
Time frame: 2-3 months. |
High fusion efficiencies
allow for increased
probability of isolating the
desired hybridoma lines.
Primary screening is
normally done by ELISA
assay; secondary,
confirmatory screening
can be custom tailored to
your particular application.
Time frame: 2-3 weeks. |
Parent Hybridoma Lines
will be selected for
cloning, isotyping and
further characterization.
This work provides for
clones stable for growth
and antibody production.
Time frame: 4-6 weeks. |
In vitro scaleup in
bioreactors provides
antibody in the 50 mg
range. Mouse antibodies
are purified by affinity
chromatography. We
accept contracts to
provide antibody from
existing cell lines.
Time frame: 4-6 weeks. |
In addition, the facility offers the service of producing antibody from existing hybridoma cell lines in the range of 50 milligrams to gram quantities utilizing hollow-fiber bioreactor technology.
The Monoclonal Antibody Core Facility is directed by Daniel Cawley, Ph.D. Dr. Cawley has managed a monoclonal antibody operation in the private sector and has commercial experience in immunoassay development.
An ongoing project at the CORE is the development of an in-house panel of mouse anti-TAG antibodies. Currently, anti-GST is available without charge to OHSU investigators.
cawleyd@ohsu.edu
|
